Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: A randomized controlled trial

JAMA

Volumn 307, Issue 6, 2012, Pages 573-582

  Gossger, Nicoletta ^a   Snape, Matthew D ^a   Yu, Ly Mee ^a   Finn, Adam ^b   Bona, Gianni ^c   Esposito, Susanna ^d   Principi, Nicola ^d   Diez Domingo, Javier ^e   Sokal, Etienne ^f   Becker, Birgitta ^g   Kieninger, Dorothee ^h   Prymula, Roman ⁱ   Dull, Peter ^j,k   Ypma, Ellen ^j,k   Toneatto, Daniela ^j,k   Kimura, Alan ^j,k   Pollard, Andrew J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e Centro Superior de Investigacion en Salud Publica CSISP   (Spain)

^f CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^g NETSTAP EV   (Germany)

^h JOHANNES GUTENBERG UNIVERSITY   (Germany)

ⁱ UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^j NOVARTIS VACCINES AND DIAGNOSTICS   (United States)

^k NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; MENINGOCOCCUS VACCINE; PERTACTIN; PNEUMOCOCCUS POLYSACCHARIDE; PNEUMOCOCCUS VACCINE;

ANTIBODY TITER; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG FEVER; DRUG TOLERABILITY; FEMALE; HUMAN; IMMUNOGENICITY; INFANT; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE SWELLING; MALE; MULTICENTER STUDY; NORMAL HUMAN; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SERUM BACTERICIDAL ACTIVITY;

EID: 84856773073     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2012.85     Document Type: Article

References (35)

1. Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine. 2009;27(suppl 2):B51-B63.
2. Menactra (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) for Intramuscular Injection [package insert]. Swiftwater, PA: Sanofi Pasteur; 2011. US Food and Drug Administration Web site. http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ ApprovedProducts/UCM131170.pdf. Accessed November 23, 2011.
3. Jackson C, Lennon DR, Sotutu VT, et al. Phase II meningococcal B vesicle vaccine trial in New Zealand infants. Arch Dis Child. 2009;94(10):745-751.
4. Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet. 2007;369(9580):2196-2210. (Pubitemid 46977462)
5. Tappero JW, Lagos R, Ballesteros AM, et al. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA. 1999;281(16):1520-1527. (Pubitemid 29200936)
6. Wong SH, Lennon DR, Jackson CM, et al. Immunogenicity and tolerability in infants of a New Zealand epidemic strain meningococcal B outer membrane vesicle vaccine. Pediatr Infect Dis J. 2009;28(5):385-390.
7. Giuliani MM, Adu-Bobie J, Comanducci M, et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci U S A. 2006;103(29):10834-10839. (Pubitemid 44148381)
8. Findlow J, Borrow R, Snape MD, et al. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis. 2010;51(10):1127-1137.
9. Snape MD, Dawson T, Oster P, et al. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr Infect Dis J. 2010;29(11):e71-e79.
10. Frasch CE, Borrow R, Donnelly J. Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease. Vaccine. 2009;27(suppl 2):B112-B116.
11. Clopper CP, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika. 1934;26(4):404-413.
12. Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med. 1985;4(2):213-226. (Pubitemid 15055349)
13. Statistical Analysis With Missing Data. Rubin DB, ed. New York, NY: John Wiley & Sons; 1987.
14. Agresti A, Coull BA. Approximate is better than "exact" for interval estimation of binomial proportions. Am Stat. 1998;52(52):119-126.
15. Ramsay ME. Current epidemiology of meningococcal disease in the UK and Europe, including issues for surveillance relating to a MenB vaccine. Presented at: Meningitis Research Foundation Conference 2011; November 8-9, 2011; London, United Kingdom.
16. Harrison LH. Epidemiological profile of meningococcal disease in the United States. Clin Infect Dis. 2010;50(suppl 2):S37-S44.
17. Campbell H, Borrow R, Salisbury D, Miller E. Meningococcal C conjugate vaccine: the experience in England and Wales. Vaccine. 2009;27(suppl 2):B20-B29.
18. Snape MD, Kelly DF, Green B, Moxon ER, Borrow R, Pollard AJ. Lack of serum bactericidal activity in preschool children two years after a single dose of sero-group C meningococcal polysaccharide-protein conjugate vaccine. Pediatr Infect Dis J. 2005;24(2):128-131. (Pubitemid 40250770)
19. Perrett KP, Winter AP, Kibwana E, et al. Antibody persistence after serogroup Cmeningococcal conjugate immunization of United Kingdom primaryschool children in 1999-2000 and response to a booster: a phase 4 clinical trial. Clin Infect Dis. 2010;50(12):1601-1610.
20. Jackson C, Lennon D, Wong S, et al. Antibody persistence following MeNZB vaccination of adults and children and response to a fourth dose in toddlers. Arch Dis Child. 2011;96(8):744-751.
21. Novartis. Safety, tolerability and immunogenicity of meningococcal B recombinant vaccine administered as booster dose at 12, 18 or 24 months of age in toddlers (12-24 months) primed with a three-dose immunization series as infants in Study V72P12 [NCT00944034]. ClinicalTrials.gov Web site. http://clinicaltrials.gov/ct2/show/NCT00944034. 2009. Accessed October 1, 2009.
22. Galloway Y, Stehr-Green P, McNicholas A, O'Hallahan J. Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years. Int J Epidemiol. 2009;38(2):413-418.
23. Holst J, Martin D, Arnold R, et al. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine. 2009;27(suppl 2):B3-B12.
24. Whitney CG, Pilishvili T, Farley MM, et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: amatched case-control study. Lancet. 2006;368(9546):1495-1502. (Pubitemid 44634693)
25. Brunelli B, Del Tordello E, Palumbo E, et al. Influence of sequence variability on bactericidal activity sera induced by Factor H binding protein variant 1.1. Vaccine. 2011;29(5):1072-1081.
26. Borrow R, Aaberge IS, Santos GF, et al. Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup b, strain 44/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine. Clin Diagn Lab Immunol. 2005;12(8):970-976.
27. Vogel U. Molecular epidemiology of meningococci: application of DNA sequence typing. Int J Med Microbiol. 2010;300(7):415-420.
28. Donnelly J, Medini D, Boccadifuoco G, et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci U S A. 2010;107(45):19490-19495.
29. Donnelly J, Medini D, Giuliani M, et al. Estimating the potential strain coverage in Europe of a multicomponent vaccine targeting serogroup B meningococci. Presented at: Meningitis Research Foundation Conference 2011; November 8-9, 2011; London, United Kingdom.
30. Smith HNM, Sloots T, Tozer S, et al. Estimating the potential strain coverage in Australia of a multicomponent vaccine targeting serogroup B meningococci. Presented at: 7th World Congress of the World Society for Pediatric Infectious Diseases (WSPID); November 16-19, 2011; Melbourne, Australia.
31. Nøkleby H, Aavitsland P, O'Hallahan J, Feiring B, Tilman S, Oster P. Safety review: two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease. Vaccine. 2007;25(16):3080-3084. (Pubitemid 46505045)
32. Waddington CS, Walker WT, Oeser C, et al. Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study. BMJ. 2010;340:c2649.
33. Kitchin N, Southern J, Morris R, et al. A randomised controlled study of the reactogenicity of an acellular pertussis-containing pentavalent infant vaccine compared to a quadrivalent whole cell pertussis-containing vaccine and oral poliomyelitis vaccine, when given concurrently with meningococcal group C conjugate vaccine to healthy UK infants at 2, 3 and 4 months of age. Vaccine. 2006;24(18):3964-3970.
34. Gustafsson L, Hallander HO, Olin P, Reizenstein E, Storsaeter J. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med. 1996;334(6):349-355. (Pubitemid 26049587)
35. Biolchi A, Kleinschmidt A, Boccadifuoco G, et al. Evaluation of the contribution of protein antigen NHBA to bactericidal antibody responses in sera from human vaccinees enrolled in clinical trials. Presented at: 17th International Pathogenic Neisseria Conference; September 11-16, 2010; Banff, Alberta, Canada.